Form 4: RXRX CEO Sells Shares Via 10b5-1 Plan

Recursion Pharmaceuticals CEO Christopher Gibson reported the sale of over 600,000 Class A shares at $5.28 each, alongside conversions and a gift, all under a pre-arranged 10b5-1 trading plan.

Summary

• Christopher Gibson, CEO and Director of Recursion Pharmaceuticals, Inc. (RXRX), reported multiple transactions involving Class A Common Stock on August 11, 2025.
• A total of 541,541 Class B Common Stock shares were automatically converted into Class A Common Stock at a price of $0.
• Gibson directly sold 500,300 Class A Common Stock shares at $5.28 per share.
• An additional 100,000 Class A Common Stock shares held indirectly by LAHWRAN-3 LLC were sold at $5.28 per share, following their conversion from Class B shares.
• 17,875 Class A Common Stock shares held indirectly by the Gibson Family Trust were also sold at $5.28 per share, after conversion from Class B shares.
• Gibson made a bona-fide gift of 10,000 Class A Common Stock shares, which were converted from Class B shares.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Gibson on May 12, 2025.
• Following these transactions, Gibson directly holds 1,004,619 Class A Common Stock shares and indirectly holds 994,619 Class A Common Stock shares (994,619 direct + 0 LAHWRAN-3 LLC + 0 Gibson Family Trust).
• Gibson retains significant derivative holdings, including 5,473,034 Class B Common Stock shares directly, and 386,000 Class B shares indirectly via LAHWRAN-3 LLC, 50,000 Class B shares indirectly via Gibson Family Trust, and 388,000 Class B shares indirectly via LAHWRAN-4 LLC, all convertible to Class A at a $0 exercise price.
• Gibson also holds various stock options to buy Class A Common Stock with exercise prices ranging from $2.48 to $11.4, and expiration dates extending to 2035.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant insider selling by the CEO. While the sales were pre-planned under a 10b5-1 plan, which mitigates some of the negative implications, the sheer volume of shares sold can still be interpreted as a lack of strong immediate upside conviction or a need for personal liquidity, which is generally not a positive signal for investors.

Positives

• The reported share sales were conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to recent non-public information.
• Christopher Gibson retains substantial direct and indirect beneficial ownership in Recursion Pharmaceuticals, including millions of Class B shares convertible to Class A and numerous stock options, demonstrating continued alignment with shareholder interests.

Negatives

• Christopher Gibson, the CEO, disposed of a significant number of Class A Common Stock shares (totaling 618,175 shares directly and indirectly) at a price of $5.28 per share.
• Insider selling, even if planned, can sometimes be perceived negatively by the market, potentially signaling a lack of immediate upside conviction or a need for personal liquidity.

Risks

• No specific risks were mentioned in the filing beyond the nature of the transactions themselves.

Future Outlook

The filing primarily details past and planned insider transactions under a Rule 10b5-1 trading plan, and ongoing vesting schedules for stock options, without providing explicit forward-looking statements on company performance or strategic guidance.

Management Comments

• All reported transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.

Industry Context

This Form 4 filing is specific to insider trading activity and does not directly provide information on broader industry trends. However, insider selling in the biotechnology and pharmaceutical sectors is often closely monitored by investors for signals regarding management's confidence in future prospects.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership and transactions through LAHWRAN-3 LLC, where the Reporting Person is a member and manager.
• Indirect beneficial ownership and transactions through the Gibson Family Trust, where the Reporting Person serves as Trustee.
• Indirect beneficial ownership through LAHWRAN-4 LLC, where the Reporting Person is a member and manager.

Stakeholder Impact

• Shareholders may interpret the significant insider selling as a negative signal, potentially impacting investor confidence and the company's stock price.
• The pre-arranged nature of the sales via a 10b5-1 plan provides transparency, which can be viewed positively by stakeholders concerned with fair and ethical insider conduct.

Next Steps

• Continued vesting of various stock options held by Christopher Gibson according to their respective schedules.
• Potential future transactions under the Rule 10b5-1 trading plan adopted on May 12, 2025.

Key Dates

Recommendation

While the CEO's significant share sales could be viewed negatively, they were conducted under a pre-arranged 10b5-1 trading plan, which suggests a structured liquidity event rather than a reaction to new adverse information. The CEO retains substantial direct and indirect holdings, including a large number of unexercised options. This filing primarily reflects a planned personal financial management action rather than a change in the company's fundamental outlook, warranting a 'hold' recommendation.

Keywords

Recursion Pharmaceuticals, RXRX, Christopher Gibson, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Biotech, Pharmaceuticals, Beneficial Ownership